Caris Life Sciences, Inc. (CAI)

Caris Life Sciences is an AI TechBio and precision medicine company, founded in 2008, that develops and commercializes molecular profiling solutions using comprehensive molecular information and AI/ML algorithms at scale. Its initial focus is oncology. Its solutions are designed to cover the cancer care continuum, including early detection, minimal residual disease (MRD) tracking, therapy selection and treatment monitoring, and it also uses its data to create molecular signatures and discover novel therapeutic targets. As of December 31, 2025, it had performed sequencing on over 1,000,000 cases, which underpins what it believes is one of the largest multi-modal clinico-genomic datasets in oncology, combining genomic data, clinical data, digitized slide images and remnant tissue.

The Caris Molecular Intelligence portfolio has three platforms. The MI Profile Platform offers tissue-based whole exome and whole transcriptome sequencing (WES/WTS), including the FDA-approved companion diagnostic MI Cancer Seek, launched in January 2025, and IHC testing, with about 170,300 clinical cases in 2025. It also includes the AI-derived signatures GPSai (tumor origin and diagnosis classification) and FOLFIRSTai, offered as laboratory developed tests. The Caris Assure Platform offers blood-based WES/WTS for therapy selection, with clonal hematopoiesis subtraction through plasma and buffy coat sequencing. Caris Assure for MRD and treatment monitoring is in development, and a technical assessment for colorectal cancer has been submitted to MolDX. The Precision Whole Genome Platform covers blood- and tissue-based whole genome sequencing, with WGS solutions anticipated in 2026, including the Caris Detect early detection assay. The company describes four platform pillars: Molecular Intelligence, Caris Discovery (AI-enabled drug target discovery), Caris Strategic Data and Caris Infrastructure.

Caris serves clinical, academic and biopharma markets. Its commercial organization specializes in precision oncology and serves over 6,000 ordering physicians in the United States across health systems, academic cancer institutions and community settings. Customers for its tests include treating physicians, researchers and biopharma companies. Biopharma partners include Moderna, AbbVie, Xencor, Merck KGaA and Genentech, which use its data and bioinformatics services to improve the odds of success for their therapeutic pipelines. In 2015 it established the Caris Precision Oncology Alliance, a global network of cancer centers and research consortia. Its tests are available in all U.S. states and Puerto Rico, except that Caris Assure is not yet available in New York, where it intends to seek NY CLEP approval. They are also offered internationally through distributors and direct hospital contracts where regulations permit. Caris Assure has Medicare reimbursement and varying commercial payer coverage. MI Cancer Seek has a PLA code (CPT 0211U) covered under the NGS NCD.

On operations, Caris relies on its own laboratory, R&D and sales infrastructure, together with high-performance and cloud computing for data analysis. Results are typically reported about seven calendar days from activation for Caris Assure and about 10 calendar days for tissue-based profiling. The company is led by its founder, Chairman and CEO, David Dean Halbert. The text does not identify specific suppliers, competitors or headquarters.